Cryptococcal Antigen Screening Plus Sertraline

Cryptococcosis Clinical Trial

— C-ASSERT  

Official title:

Cryptococcal Antigen Screening Plus Sertraline

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03002012
• Other study ID #: U01AI125003
• Secondary ID: U01AI12500333238
• Status: Terminated
• Phase: Phase 3
• Start date: November 15, 2017
• Est. completion date: March 13, 2018

Study information

• Verified date: June 2020
• Source: University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cryptococcal meningitis or "Crypto" is a life threatening fungal infection around the brain that requires hospitalization for treatment for 14 days and then continued therapy. Crypto causes 15-20% of HIV/AIDS-related deaths worldwide. However, this infection can be detected before one develops symptoms and becomes ill. People can be screened for infection by a blood test to detect "cryptococcal antigen," (called CrAg), which is part of the fungus, in blood. The World Health Organization and over 22 countries worldwide recommend CrAg screening of all persons with advanced AIDS entering or re-entering into HIV care.

However, it is not known how best to treat people with cryptococcal antigen in their blood, who don't otherwise yet have symptoms of infection around their brain. If no treatment is given, almost all people will develop infection of the brain and/or die. International guidelines suggest using both HIV medicines and an anti-fungal medicine, called fluconazole, to treat this early infection. However, despite this treatment approximately 1 in 4 people may get sick and/or die.

Researchers have recently discovered another medicine that may work against the Cryptococcus fungus. This medicine is called Sertraline, and it is actually a medicine that has been used for more than 25 years to treat depression (sadness). Sertraline is one of the most commonly used medicines worldwide.

The purpose of this research clinical trial is to determine if standard fluconazole antifungal therapy plus a high dose of Sertraline, will be better than standard fluconazole therapy alone for treating early disseminated cryptococcal infection in persons who are asymptomatic and do not yet have infection of the brain (i.e. meningitis).

This study seeks to test if Sertraline will improve survival through 6-months. Prior studies have shown that >90% of those who survive 6-months will survive >5 years.

Description:

This is a double-blind, randomized placebo-controlled clinical trial testing sertraline as an antifungal medicine in combination with fluconazole for treatment of HIV-infected persons with AIDS and asymptomatic cryptococcal antigenemia (CrAg+).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 22
• Est. completion date: March 13, 2018
• Est. primary completion date: March 13, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• HIV-infected

• Cryptococcal antigen (CrAg) positive in blood

• Age >=18 years

• Written informed consent

• Women of childbearing potential who are participating in sexual activity that could lead to pregnancy must agree to use one reliable method of contraception while receiving fluconazole >=400mg/day

Exclusion Criteria:

• Prior history of cryptococcal meningitis

• Suspected meningitis or mania

• Suspected/known cirrhosis, jaundice, or alanine aminotransferase (ALT) >5x upper limit of normal

• Receiving an antidepressant medicine

• Receiving antifungal therapy, >1 week

• Pregnant or Breastfeeding

• Contraindication to sertraline or fluconazole

• Current rifampin use or other prohibited medication

• Electrocardiogram corrected QT interval (QTc) >450ms

Related Conditions & MeSH terms

• AIDS-Related Opportunistic Infections
• Communicable Diseases
• Cryptococcal Infections
• Cryptococcosis
• Infection
• Opportunistic Infections

Intervention

Drug:
• Sertraline
sertraline 400mg/day
• Placebo Oral Tablet
matched placebo tablet
• Fluconazole
Standard of Care Fluconazole per World Health Organization and Ugandan Guidelines (800mg/day x 2 weeks, 400mg/day x10 weeks, 200mg through 6 months).

Locations

Country	Name	City	State
Uganda	Infectious Disease Institute, Makerere University	Kampala

Sponsors (4)

Lead Sponsor	Collaborator
University of Minnesota	Infectious Diseases Institute, Uganda, Mbarara University of Science and Technology, National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

Uganda, 

References & Publications (1)

Boulware DR, Nalintya E, Rajasingham R, Kirumira P, Naluyima R, Turya F, Namanda S, Rutakingirwa MK, Skipper CP, Nikweri Y, Hullsiek KH, Bangdiwala AS, Meya DB. Adjunctive sertraline for asymptomatic cryptococcal antigenemia: A randomized clinical trial. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Adherence to Study Drug	Participants' percent adherence to study drug regiment by pharmacy medication counts, representing the percent of the total prescribed medication taken by participants.	12 weeks
Primary	6 Month Meningitis-free Survival	Cryptococcal meningitis free survival with retention-in-care through 6 months; Those who die of any cause are failures; Those developing symptomatic cryptococcal meningitis are failures; Those lost to follow up and unable to be tracked are considered failures	6 months
Secondary	6-month Survival	Survival through 6 months	6 months
Secondary	Cumulative Incidence of Symptomatic Cryptococcal Meningoencephalitis	Cumulative incidence of symptomatic cryptococcal meningoencephalitis through 6 months	6 months
Secondary	Number of Clinical Adverse Events (Grade 3-5)	Number of Clinical Adverse Events by Division of AIDS (DAIDS) Scale for Grade 3-5 events through 6 months	6 months
Secondary	Number of Laboratory Grade 3-5 Adverse Events	Number of Laboratory Grade 3-5 Adverse Events through 6 months as per the Division of AIDS (DAIDS) grading scale	6 months
Secondary	All-Cause Premature Study Drug/Placebo Discontinuation	Number of participants whose study drug/placebo use was halted prematurely due to any cause through 6 months	6 months
Secondary	Prevalence of Depression by Patient Health Questionnaire (PHQ-9) Over Time	Prevalence of depression by Patient Health Questionnaire (PHQ-9) over 6 months as measured at baseline, 4 weeks, 8 weeks, and 12 weeks. The PHQ-9 is a 9-item instrument for screening, diagnosing, monitoring, and measuring the severity of depression. Items are rated on a scale from 0 (not at all) to 3 (nearly every day). Total score is a sum of 9 item scores (Range 0-27). Greater scores indicate greater depressive symptoms. PHQ-9 scores of: 0-4 Minimal/No depression; 5-9 Mild depression; 10-14 Moderate depression; 15-19 Moderate severe depression; 20-27 Severe depression. This endpoint reports the median (interquartile range) of the PHQ-9 scores over time.	12 weeks

External Links

•   Global Action Fund for Fungal Infections (GAFFI)
•   PreventCrypto.org has information and training materials for cryptococcal antigen screening and treatment
•   Preventing Deaths from Cryptococcal Meningitis